These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program. van Leeuwen LPM; Grobben M; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk FL; van Gils MJ; de Vries RD; Dalm VASH; Front Immunol; 2024; 15():1390022. PubMed ID: 38698851 [TBL] [Abstract][Full Text] [Related]
4. Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination. Younes S; Nicolai E; Pieri M; Bernardini S; Daas HI; Al-Sadeq DW; Younes N; Shurrab FM; Nizamuddin PB; Humaira F; Al-Dewik N; Yassine HM; Abu-Raddad LJ; Ismail A; Nasrallah GK Influenza Other Respir Viruses; 2024 May; 18(5):e13290. PubMed ID: 38706402 [TBL] [Abstract][Full Text] [Related]
5. Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination. Gorochov G; Ropers J; Launay O; Dorgham K; da Mata-Jardin O; Lebbah S; Durier C; Bauer R; Radenne A; Desaint C; Vieillard LV; Rekacewicz C; Lachatre M; Parfait B; Batteux F; Hupé P; Ninove L; Lefebvre M; Conrad A; Dussol B; Maakaroun-Vermesse Z; Melica G; Nicolas JF; Verdon R; Kiladjian JJ; Loubet P; Schmidt-Mutter C; Dualé C; Ansart S; Botelho-Nevers E; Lelièvre JD; de Lamballerie X; Kieny MP; Tartour E; Paul S JAMA Netw Open; 2024 Apr; 7(4):e248051. PubMed ID: 38652471 [TBL] [Abstract][Full Text] [Related]
6. Salivary and serum IgA and IgG responses to SARS-CoV-2-spike protein following SARS-CoV-2 infection and after immunization with COVID-19 vaccines. Li D; Calderone R; Nsouli TM; Reznikov E; Bellanti JA Allergy Asthma Proc; 2022 Sep; 43(5):419-430. PubMed ID: 36065108 [No Abstract] [Full Text] [Related]
7. Follow-up SARS-CoV-2 serological study of a health care worker cohort following COVID-19 booster vaccination. Hönning A; Tomczyk S; Hermes J; Grossegesse M; Hofmann N; Michel J; Neumann M; Nitsche A; Hoppe B; Eckmanns T; Schmidt-Traub H; Zappel K BMC Infect Dis; 2024 Apr; 24(1):436. PubMed ID: 38658874 [TBL] [Abstract][Full Text] [Related]
8. Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies. Chen S; Zhang Z; Wang Q; Yang Q; Yin L; Ning L; Chen Z; Tang J; Deng W; He P; Li H; Shi L; Deng Y; Liu Z; Bu H; Zhu Y; Liu W; Qu L; Feng L; Xiong X; Sun B; Zhong N; Li F; Li P; Chen X; Chen L Signal Transduct Target Ther; 2024 Jul; 9(1):190. PubMed ID: 39039046 [TBL] [Abstract][Full Text] [Related]
9. Hybrid immunity by two COVID-19 mRNA vaccinations and one breakthrough infection provides a robust and balanced cellular immune response as basic immunity against severe acute respiratory syndrome coronavirus 2. Almanzar G; Koosha K; Vogt T; Stein A; Ziegler L; Asam C; Weps M; Schwägerl V; Richter L; Hepp N; Fuchs A; Wagenhäuser I; Reusch J; Krone M; Geldmacher C; Protzer U; Steininger P; Überla K; Wagner R; Liese J; Prelog M J Med Virol; 2024 Jun; 96(6):e29739. PubMed ID: 38899449 [TBL] [Abstract][Full Text] [Related]
10. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery. Yang YJ; Murphy EA; Singh S; Sukhu AC; Wolfe I; Adurty S; Eng D; Yee J; Mohammed I; Zhao Z; Riley LE; Prabhu M Obstet Gynecol; 2022 Mar; 139(3):373-380. PubMed ID: 34963127 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of Two Doses of BNT162b2 mRNA COVID-19 Vaccine with a ChAdOx1-S Booster Dose among Navy Personnel in Mexico. Ventura-Enríquez Y; Cortina-De la Rosa E; Díaz-Padilla E; Murrieta S; Segundo-Martínez S; Fernández-Sánchez V; Vargas-De-León C Viruses; 2024 Apr; 16(4):. PubMed ID: 38675894 [TBL] [Abstract][Full Text] [Related]
12. Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals. Klingler J; Lambert GS; Itri V; Liu S; Bandres JC; Enyindah-Asonye G; Liu X; Simon V; Gleason CR; Kleiner G; Chiu HP; Hung CT; Kowdle S; Amanat F; Lee B; Zolla-Pazner S; Upadhyay C; Hioe CE Front Immunol; 2021; 12():759688. PubMed ID: 34987505 [TBL] [Abstract][Full Text] [Related]
13. Proteomic and Cellular Characterization of Omicron Breakthrough Infections and a Third Homologous or Heterologous Boosting Vaccination in a Longitudinal Cohort. Zhang Y; Fu Z; Zhang H; Lin K; Song J; Guo J; Zhang Q; Yuan G; Wang H; Fan M; Zhao Y; Sun R; Guo T; Jiang N; Qiu C; Zhang W; Ai J Mol Cell Proteomics; 2024 Jun; 23(6):100769. PubMed ID: 38641227 [TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836 [TBL] [Abstract][Full Text] [Related]
18. Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine. Duarte LF; Gálvez NMS; Iturriaga C; Melo-González F; Soto JA; Schultz BM; Urzúa M; González LA; Vázquez Y; Ríos M; Berríos-Rojas RV; Rivera-Pérez D; Moreno-Tapia D; Pacheco GA; Vallejos OP; Hoppe-Elsholz G; Navarrete MS; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Bueno SM; Kalergis AM Front Immunol; 2021; 12():742914. PubMed ID: 34659237 [TBL] [Abstract][Full Text] [Related]
19. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection. van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP Front Immunol; 2021; 12():781280. PubMed ID: 34987509 [TBL] [Abstract][Full Text] [Related]
20. Protective role of SARS-CoV-2 anti-S IgG against breakthrough infections among European healthcare workers during pre and post-Omicron surge-ORCHESTRA project. Spiteri G; D'Agostini M; Abedini M; Ditano G; Collatuzzo G; Boffetta P; Vimercati L; Sansone E; De Palma G; Modenese A; Gobba F; Liviero F; Moretto A; dell'Omo M; Fiordi T; Larese Filon F; Mauro M; Violán C; Mates D; Oravec Bérešová J; Monaco MGL; Carta A; Verlato G; Porru S Infection; 2024 Aug; 52(4):1347-1356. PubMed ID: 38326526 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]